Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

Study on Shot vs Vein Treatment for Multiple Sclerosis

Recruiting
18 years - 60 years
All
Phase 3
160 participants needed
9 Locations

Study Overview

This is a randomized, open-label, parallel, Phase 3 study with 2-arms for treatment.

The purpose of this study is to evaluate SC administration of frexalimab every 4 weeks (q4w) compared to IV administration of frexalimab q4w in male and female participants with RMS and nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with MS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria.

Study details include:

The study intervention duration will be 48 weeks (12 months) for Parts A and B combined. Optional Part C will last until the initiation of a long term safety study for Frexalimab.The follow up duration after the end of study intervention (in case of discontinuation) will be 6 months.

The number of scheduled visits (Parts A and B) will be 17 or 11 for participants receiving frexalimab SC or IV, respectively, with an on-site visit frequency of every month between Week 4 and Week 24 in Part A, then every 1 to 3 months in Part B, then every 6 months in Part C. Participants discontinuing treatment before the End of Study will have an additional 3 follow-up visits.

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions: Multiple Sclerosis
  • Age: 18 years - 60 years
  • Gender: All

Inclusion Criteria:

The participant must qualify for inclusion per either Group A or B criteria as detailed below, meeting all the inclusion criteria of the applicable group:

Group A (RMS)

  • The participant must be 18 to 55 years of age, inclusive, at the time of signing the informed consent.
  • The participant must have been diagnosed with RMS in accordance with the 2017 revised McDonald criteria.
  • The participant must have an Expanded Disability Status Scale (EDSS) score of ≤5.5 at the first visit (Screening Visit).

  • The participant must have at least 1 of the following prior to screening:

    • 1 documented relapse within the previous year OR
    • 2 documented relapses within the previous 2 years, OR
    • 1 documented Gd enhancing lesion on an MRI scan within the previous year. Group B (nrSPMS)
  • Participant must have a previous diagnosis of RRMS in accordance with the 2017 revised McDonald criteria
  • The participant must be 18 to 60 years of age, inclusive, at the time of signing the informed consent.
  • The participant must have a current diagnosis of SPMS in accordance with the clinical course criteria revised in 2013.
  • The participant must have documented evidence of disability progression observed during the 12 months before screening.
  • The participant must have an absence of clinical relapses for at least 24 months.
  • The participant must have an EDSS score between 3.0 and 6.5 points, inclusive, at the first visit (Screening Visit).

Participants from Group A and Group B are eligible to be included in the study only if all of the following criteria also apply:

- Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion Criteria:

  • The participant has been diagnosed with primary progressive MS according to the 2017 revision of the McDonald diagnostic criteria.
  • The participant has a history of infection or may be at risk for infection:
  • Fever within 28 days of the Screening Visit
  • Presence of psychiatric disturbance or substance abuse
  • History, clinical evidence, suspicion or significant risk for thromboembolic events, as well as myocardial infarction, stroke, and/or antiphospholipid syndrome and any participants requiring antithrombotic treatment.
  • Current hypogammaglobulinemia defined by Ig levels (IgG and/or IgM) below the LLN at screening or a history of primary hypogammaglobulinemia.
  • A history or presence of disease that can mimic MS symptoms.
  • The participant has a contraindication for MRI.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

This study investigates how a medicine given by shot under the skin compares to being given through a vein for people with Multiple Sclerosis (MS). Participants will be in the study for 48 weeks, which is about 12 months.

Participants will either get the medicine through a shot under the skin or through a vein. There will be regular check-ups to see how the treatment is working and to ensure the safety of participants.

  • Who can participate: Adults aged 18 to 60 with relapsing MS or secondary progressive MS may join. Participants need to meet specific health criteria and must not have primary progressive MS or certain health conditions.
  • Study details: Participants will receive the investigational medicine either through a shot under the skin or through a vein every four weeks. They will have regular health check-ups to monitor their condition. An inactive substance that looks like the investigational medicine/vaccine but does not contain any medicine is not used in this study.
  • Study timelines: The study will last 48 weeks.
Updated on 13 Mar 2026. Study ID: NCT07325292

Find a study site near you

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
United States Only: Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language